CoChat

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial

Open access
Butler, Javed, Anker, Stefan D, Lund, Lars H, Coats, Andrew J S, Filippatos, Gerasimos, Siddiqi, Tariq Jamal, Friede, Tim, Fabien, Vincent, Kosiborod, Mikhail, Metra, Marco, Piña, Ileana L, Pinto, Fausto, Rossignol, Patrick, van der Meer, Peter, Bahit, Cecilia, Belohlavek, Jan, Böhm, Michael, Brugts, Jasper J, Cleland, John G F, Ezekowitz, Justin, Bayes-Genis, Antoni, Gotsman, Israel, Goudev, Assen, Khintibidze, Irakli, Lindenfeld, Joann, Mentz, Robert J, Merkely, Bela, Montes, Eliodoro Castro, Mullens, Wilfried, Nicolau, Jose C, Parkhomenko, Aleksandr, Ponikowski, Piotr, Seferovic, Petar M, Senni, Michele, Shlyakhto, Evgeny, Cohen-Solal, Alain, Szecsödy, Peter, Jensen, Klaus, Dorigotti, Fabio, Weir, Matthew R, Pitt, Bertram · 2022 · European Heart Journal
Cited by 231

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aims: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin–angiotensin–aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results: A total of 1642 patients with HFrEF and current or a history of RAASi-related hyperkalemia were screened and 1195 were enrolled in the run-in phase with patiromer and optimization of the RAASi therapy [≥50% recommended dose of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, and 50 mg of mineralocorticoid receptor antagonist (MRA) spironolactone or eplerenone]. Specified target doses of the RAASi therapy were achieved in 878 (84.6%) patients; 439 were randomized to patiromer and 439 to placebo. All patients, physicians, and outcome assessors were blinded to treatment assignment. The primary endpoint was between-group difference in the adjusted mean change in serum potassium. Five hierarchical secondary endpoints were assessed. At the end of treatment, the median (interquartile range) duration of follow-up was 27 (13–43) weeks, the adjusted mean change in potassium was +0.03 mmol/l in the patiromer group and +0.13 mmol/l in the placebo group [difference in the adjusted mean change between patiromer and placebo: −0.10 mmol/l (95% confidence interval, CI −0.13, 0.07); P < 0.001]. Risk of hyperkalemia >5.5 mmol/l [hazard ratio (HR) 0.63; 95% CI 0.45, 0.87; P = 0.006), reduction of MRA dose (HR 0.62; 95% CI 0.45, 0.87; P = 0.006), and total adjusted hyperkalemia events/100 person-years (77.7 vs. 118.2; HR 0.66; 95% CI 0.53, 0.81; P < 0.001) were lower with patiromer. Hyperkalemia-related morbidity-adjusted events (win ratio 1.53, P < 0.001) and total RAASi use score (win ratio 1.25, P = 0.048) favored the patiromer arm. Adverse events were similar between groups. Conclusion: Concurrent use of patiromer and high-dose MRAs reduces the risk of recurrent hyperkalemia (ClinicalTrials.gov: NCT03888066).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehac401

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 231

Metadata

Authors
Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., Piña, I. L., Pinto, F., Rossignol, P., van der Meer, P., Bahit, C., Belohlavek, J., Böhm, M., Brugts, J. J., Cleland, J. G. F., Ezekowitz, J., Bayes-Genis, A., Gotsman, I., Goudev, A., Khintibidze, I., Lindenfeld, J., Mentz, R. J., Merkely, B., Montes, E. C., Mullens, W., Nicolau, J. C., Parkhomenko, A., Ponikowski, P., Seferovic, P. M., Senni, M., Shlyakhto, E., Cohen-Solal, A., Szecsödy, P., Jensen, K., Dorigotti, F., Weir, M. R., & Pitt, B.
Venue
European Heart Journal
Published
2022-08-23
Volume
43
Issue
41
Pages
4362-4373
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4288445068
Cited by
231
References
5
FWCI
25.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehac401
The paper
Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., Piña, I. L., Pinto, F., Rossignol, P., van der Meer, P., Bahit, C., Belohlavek, J., Böhm, M., Brugts, J. J., Cleland, J. G. F., . . . Pitt, B. (2022). Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac401

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.